STOCK TITAN

MacroGenics (NASDAQ: MGNX) insider lines up new stock sale after recent trade

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

MacroGenics, Inc. (symbol MGNX) has a notice of proposed resale of its common stock under Form 144. The filing lists 42,080 shares of common stock to be sold through Merrill Lynch, with a proposed sale date of 08/17/2026 on NASDAQ.

The seller is identified as Jay Siegel, with a section also listing securities sold during the past 3 months: on 08/03/2026, a transaction in common stock for 34,916 shares is reported, alongside a related value of 130,905. Another numeric identifier 63,700,187 appears in the securities information section.

Positive

  • None.

Negative

  • None.
Proposed shares to be sold 42,080 shares Common stock listed with Merrill Lynch with proposed sale date 08/17/2026
Proposed sale date 08/17/2026 Date associated with 42,080 shares of common stock to be sold on NASDAQ
Shares sold during past 3 months 34,916 shares Common stock transaction dated 08/03/2026 in the past 3 months section
Related value for past sale 130,905 Figure reported alongside 34,916 shares sold on 08/03/2026
Security identifier 63,700,187 Numeric identifier shown in the securities information line for common stock
Form 144 regulatory
"144: Filer Information | | | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Securities To Be Sold financial
"144: Securities To Be Sold Common | 08/17/2026 | Stock plan activity"
Securities Sold During The Past 3 Months financial
"144: Securities Sold During The Past 3 Months Jay Siegel"
stock plan activity financial
"Common | 08/17/2026 | Stock plan activity | Issuer"

FAQ

What does MacroGenics (MGNX) report in this Form 144 filing?

MacroGenics (MGNX) reports a Form 144 notice for a proposed resale of 42,080 shares of its common stock. The shares are planned to be sold through Merrill Lynch on or after 08/17/2026 on NASDAQ.

How many MacroGenics (MGNX) shares are proposed to be sold under this Form 144?

The Form 144 indicates a proposed sale of 42,080 shares of MacroGenics common stock. These shares are listed under the securities information section with Merrill Lynch as broker and a proposed sale date of 08/17/2026.

Who is the reporting person in the MacroGenics (MGNX) Form 144?

The reporting person is Jay Siegel, with an address in Rockville, Maryland. His name appears in the section describing securities sold during the past 3 months, linked to prior sales of MacroGenics common stock.

What prior sales are disclosed in the MacroGenics (MGNX) Form 144?

The filing notes that on 08/03/2026, 34,916 shares of MacroGenics common stock were sold. This transaction is listed with a related figure of 130,905 in the “Securities Sold During The Past 3 Months” section.

On which market are the MacroGenics (MGNX) shares in this Form 144 expected to trade?

The shares in this Form 144 are associated with NASDAQ. The securities information section specifies NASDAQ as the market for the proposed sale of 42,080 shares of MacroGenics common stock.

Which broker is named in the MacroGenics (MGNX) Form 144 transaction?

The broker named is Merrill Lynch, with an address at 1800 K St NW, Suite 800, Washington, DC 20006. Merrill Lynch is listed in connection with the proposed sale of 42,080 shares of MacroGenics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature